ADMA Biologics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $124.4 million, up 2% year-over-year.

ASCENIV Revenue: $102.9 million, a 24% increase year-over-year.

BIVIGAM Revenue: $19.4 million, showing sequential improvement.

Gross Profit: $86.3 million, with a gross margin of 69%, improved from 55% in the prior year.

Adjusted EBITDA: $61.8 million, up 22% year-over-year.

Adjusted Net Income: $39 million, an 8% increase year-over-year.

GAAP Net Income: $37.8 million, an 11% increase year-over-year.

Cash Position: $136 million in cash and equivalents, with net leverage below 0.5 turns.

Share Repurchases: 7.1 million shares repurchased during the quarter, totaling 13.8 million shares year-to-date.

2Strategic Updates and Business Highlights

ASCENIV Demand: Strong growth driven by increased physician adoption and patient utilization, with June showing the strongest sequential growth since early 2024.

Real-World Evidence: Positive outcomes from a study on ASCENIV presented at the upcoming American College of Allergy, Asthma and Immunology meeting, highlighting significant reductions in hospitalizations and healthcare utilization among patients.

Manufacturing Efficiency: Continued benefits from a yield-enhanced manufacturing process and diversified plasma sourcing strategy.

SG-001 Development: Progressing towards a pre-IND submission to the FDA by year-end, with potential for substantial revenue opportunity if approved.

3Forward Guidance and Outlook

2026 Financial Guidance: Reiterated expectations for total revenue of $530 million to $560 million, adjusted EBITDA of $265 million to $300 million, and adjusted net income of $170 million to $200 million.

Growth Drivers: Anticipated continued growth from ASCENIV through increased patient utilization, physician adoption, and payer access.

4Bad News, Challenges, or Points of Concern

Competitive Pressures: Ongoing challenges in the U.S. immunoglobulin market, particularly for BIVIGAM, which remains down year-over-year despite signs of stabilization.

Market Dynamics: Increased supply and competitive pricing pressures in the standard immunoglobulin market could impact profitability.

Tax Rate Increase: Effective tax rate rose to 24.7%, affecting net income.

5Notable Q&A Insights

McKesson Partnership: The collaboration is expected to enhance ASCENIV penetration, with faster payment terms compared to other customers.

Reimbursement Dynamics: Broad access for ASCENIV remains stable, with no significant negative changes noted in reimbursement.

BIVIGAM Outlook: While stabilization is observed, it is still expected to be down 40-50% from 2025 levels.

Future Growth in Secondary Immunodeficiency: Potential for growth in secondary immune deficiency markets is acknowledged, but current focus remains on primary immunodeficiency patients. Overall, ADMA Biologics demonstrated solid financial performance in Q2 2026, with ASCENIV showing strong growth potential despite competitive pressures in the broader immunoglobulin market. The company remains optimistic about its strategic initiatives and future growth drivers while acknowledging ongoing challenges.